TP53 G266R

CI-VAR-00001690Explore in graph →ClinVar 458566 CIViC 1055 rs1057519990

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease3unmapped disease
TP53 G266R	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID9463 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
TP53 G266R	(functional)	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10230 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
458566	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Li-Fraumeni syndrome; Ovarian neoplasm; Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome 1; Neoplasm; Adrenocortical carcinoma, hereditary	germline/somatic	7	Apr 25, 2024	clinvar